Recent trends in pirfenidone and nintedanib use for idiopathic pulmonary fibrosis in Australia

被引：3

作者：

Cox, Ingrid A. ^{[1
,2
]}

de Graaff, Barbara ^{[1
,2
]}

Corte, Tamera J. ^{[2
,6
,7
]}

Glaspole, Ian ^{[2
,8
,9
]}

Chambers, Daniel C. ^{[3
,10
,11
]}

Moodley, Yuben ^{[4
,12
,13
,14
]}

Teoh, Alan ^{[2
,7
]}

Walters, E. Haydn ^{[1
,2
]}

Palmer, Andrew J. ^{[1
,5
,15
]}

机构：

[1] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia

[2] Natl Hlth & Med Res Council NHMRC, Ctr Res Excellence Pulm Fibrosis, Camperdown, NSW, Australia

[3] Natl Hlth & Med Res Council NHMRC, Ctr Res Excellence Pulm Fibrosis, Queensland Lung Transplant Serv, Camperdown, NSW, Australia

[4] Natl Hlth & Med Res Council NHMRC, Ctr Res Excellence Pulm Fibrosis, Stem Cell Therapy Unit, Inst Resp Hlth, Camperdown, NSW, Australia

[5] Natl Hlth & Med Res Council NHMRC, Ctr Res Excellence Pulm Fibrosis, Publ Hlth Primary Care & Hlth Serv, Camperdown, NSW, Australia

[6] Univ Sydney, Cent Clin Sch, Camperdown, NSW, Australia

[7] Royal Prince Alfred Hosp, Dept Resp & Sleep Med, Camperdown, NSW, Australia

[8] Alfred Hosp, Interstitial Lung Dis Clin, Melbourne, Vic, Australia

[9] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia

[10] Univ Queensland, Sch Clin Med, Brisbane, Qld, Australia

[11] Prince Charles Hosp, Queensland Lung Transplant Serv, Brisbane, Qld, Australia

[12] Univ Western Australia, Fac Hlth & Med Sci, Perth, WA, Australia

[13] Univ Western Australia, Inst Resp Hlth, Perth, WA, Australia

[14] Fiona Stanley Hosp, Dept Resp Med, Murdoch, WA, Australia

[15] Univ Melbourne, Sch Populat & Global Hlth, Ctr Hlth Policy, Melbourne, Vic, Australia

来源：

AUSTRALIAN HEALTH REVIEW | 2021年 / 45卷 / 06期

基金：

澳大利亚国家健康与医学研究理事会;

关键词：

antifibrotics; phannacoepidemiology; health economics; health funding and financing; interstitial lung disease; idiopathic pulmonary fibrosis; medication costs; pharmaceuticals; PREVALENCE;

D O I：

10.1071/AH20337

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Objectives. Idiopathic pulmonary fibrosis (IPF) is one of the most common forms of interstitial lung disease presenting in people aged >= 50 years. There is currently no cure for IPF, but two medications (pirfenidone and nintedanib) have been shown to slow the functional decline of the lungs. In 2017, these two medications were listed on the Pharmaceutical Benefits Scheme (PBS) for subsidisation in Australia. This study evaluated local trends in the use of these two medications. Methods. Prescription data for this analysis were obtained from the PBS Item Reports for the period May 2017 May 2020. Population data were extracted from the Australian Bureau of Statistics data cubes. A descriptive approach was used to conduct and report the analysis to illustrate trends in the use of these two medications and associated costs. Results. There were 44 010 prescriptions processed for the treatment for IPF in the 3-year period. Nintedanib use was higher than pirfenidone use, accounting for 54% of prescriptions. New South Wales accounted for 35% of the total prescriptions but, when standardised against population size, the Australian Capital Territory accounted for the highest proportion of prescriptions (24%). Prescriptions for nintedanib and pirfenidone were associated with a total cost of A$131 377 951 over the period 2017-20. Conclusion. This study provides initial information on prescription rates, practices and expenditure for pirfenidone and nintedanib. In addition, we provide some insight into possible pharmacological and epidemiological trends based on jurisdictional differences. Together, the results from this study provide a platform for future research given the dearth of information on IPF in Australia.

引用

页码：718 / 727

页数：10

共 30 条

[1]

[Anonymous], 2020, PHARM BENEFITS SCHEM

[2] Idiopathic pulmonary fibrosis: Physicians ' perceptions of patient treatment with recently approved drugs [J].